Upcoming event
40th Annual EAU Congress
Back

Tag: Abiraterone

Abiraterone in “high-” and “low-risk” metastatic hormone-sensitive prostate cancer

Wnt-pathway activating mutations are associated with resistance to first-line abiraterone and enzalutamide in castration-resistant prostate cancer

PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer

The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer

PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate

Efficacy of Enzalutamide Following Abiraterone Acetate in Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer Patients